Literature DB >> 22514280

Lipodepsipeptide empedopeptin inhibits cell wall biosynthesis through Ca2+-dependent complex formation with peptidoglycan precursors.

Anna Müller1, Daniela Münch, Yvonne Schmidt, Katrin Reder-Christ, Guido Schiffer, Gerd Bendas, Harald Gross, Hans-Georg Sahl, Tanja Schneider, Heike Brötz-Oesterhelt.   

Abstract

Empedopeptin is a natural lipodepsipeptide antibiotic with potent antibacterial activity against multiresistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae in vitro and in animal models of bacterial infection. Here, we describe its so far elusive mechanism of antibacterial action. Empedopeptin selectively interferes with late stages of cell wall biosynthesis in intact bacterial cells as demonstrated by inhibition of N-acetylglucosamine incorporation into polymeric cell wall and the accumulation of the ultimate soluble peptidoglycan precursor UDP-N-acetylmuramic acid-pentapeptide in the cytoplasm. Using membrane preparations and the complete cascade of purified, recombinant late stage peptidoglycan biosynthetic enzymes and their respective purified substrates, we show that empedopeptin forms complexes with undecaprenyl pyrophosphate containing peptidoglycan precursors. The primary physiological target of empedopeptin is undecaprenyl pyrophosphate-N-acetylmuramic acid(pentapeptide)-N-acetylglucosamine (lipid II), which is readily accessible at the outside of the cell and which forms a complex with the antibiotic in a 1:2 molar stoichiometry. Lipid II is bound in a region that involves at least the pyrophosphate group, the first sugar, and the proximal parts of stem peptide and undecaprenyl chain. Undecaprenyl pyrophosphate and also teichoic acid precursors are bound with lower affinity and constitute additional targets. Calcium ions are crucial for the antibacterial activity of empedopeptin as they promote stronger interaction with its targets and with negatively charged phospholipids in the membrane. Based on the high structural similarity of empedopeptin to the tripropeptins and plusbacins, we propose this mechanism of action for the whole compound class.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22514280      PMCID: PMC3370209          DOI: 10.1074/jbc.M112.369561

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Isolation and characterization of new peptide antibiotics, plusbacins A1-A4 and B1-B4.

Authors:  J Shoji; H Hinoo; T Katayama; K Matsumoto; T Tanimoto; T Hattori; I Higashiyama; H Miwa; K Motokawa; T Yoshida
Journal:  J Antibiot (Tokyo)       Date:  1992-06       Impact factor: 2.649

Review 2.  Antibacterial activities and modes of action of vancomycin and related glycopeptides.

Authors:  R Nagarajan
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Characterization of the lipid-carrier involved in the synthesis of enterobacterial common antigen (ECA) and identification of a novel phosphoglyceride in a mutant of Salmonella typhimurium defective in ECA synthesis.

Authors:  P D Rick; G L Hubbard; M Kitaoka; H Nagaki; T Kinoshita; S Dowd; V Simplaceanu; C Ho
Journal:  Glycobiology       Date:  1998-06       Impact factor: 4.313

4.  The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation.

Authors:  H Brötz; G Bierbaum; P E Reynolds; H G Sahl
Journal:  Eur J Biochem       Date:  1997-05-15

5.  Temporal activation of beta-glucanase synthesis in Bacillus subtilis is mediated by the GTP pool.

Authors:  J Stülke; R Hanschke; M Hecker
Journal:  J Gen Microbiol       Date:  1993-09

6.  Analysis of murein and murein precursors during antibiotic-induced lysis of Escherichia coli.

Authors:  U Kohlrausch; J V Höltje
Journal:  J Bacteriol       Date:  1991-06       Impact factor: 3.490

7.  The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II.

Authors:  H Brötz; G Bierbaum; K Leopold; P E Reynolds; H G Sahl
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

8.  murH, a new genetic locus in Escherichia coli involved in cell wall peptidoglycan biosynthesis.

Authors:  D Dai; E E Ishiguro
Journal:  J Bacteriol       Date:  1988-05       Impact factor: 3.490

9.  Structures of new peptide antibiotics, plusbacins A1-A4 and B1-B4.

Authors:  J Shoji; H Hinoo; T Katayama; Y Nakagawa; Y Ikenishi; K Iwatani; T Yoshida
Journal:  J Antibiot (Tokyo)       Date:  1992-06       Impact factor: 2.649

10.  Tripropeptins, novel antimicrobial agents produced by Lysobacter sp.

Authors:  Hideki Hashizume; Sehei Hirosawa; Ryuichi Sawa; Yasuhiko Muraoka; Daishiro Ikeda; Hiroshi Naganawa; Masayuki Igarashi
Journal:  J Antibiot (Tokyo)       Date:  2004-01       Impact factor: 2.649

View more
  6 in total

Review 1.  Advancing cell wall inhibitors towards clinical applications.

Authors:  Sonia I Maffioli; João C S Cruz; Paolo Monciardini; Margherita Sosio; Stefano Donadio
Journal:  J Ind Microbiol Biotechnol       Date:  2015-10-29       Impact factor: 3.346

Review 2.  Targeting the Achilles' Heel of Bacteria: Different Mechanisms To Break Down the Peptidoglycan Cell Wall during Bacterial Warfare.

Authors:  Stephanie Sibinelli-Sousa; Julia Takuno Hespanhol; Ethel Bayer-Santos
Journal:  J Bacteriol       Date:  2021-03-08       Impact factor: 3.490

3.  Lipid Requirements for the Enzymatic Activity of MraY Translocases and in Vitro Reconstitution of the Lipid II Synthesis Pathway.

Authors:  Erik Henrich; Yi Ma; Ina Engels; Daniela Münch; Christian Otten; Tanja Schneider; Beate Henrichfreise; Hans-Georg Sahl; Volker Dötsch; Frank Bernhard
Journal:  J Biol Chem       Date:  2015-11-30       Impact factor: 5.157

Review 4.  Advances in MRSA drug discovery: where are we and where do we need to be?

Authors:  Michio Kurosu; Shajila Siricilla; Katsuhiko Mitachi
Journal:  Expert Opin Drug Discov       Date:  2013-07-06       Impact factor: 6.098

5.  The Draft Whole-Genome Sequence of the Antibiotic Producer Empedobacter haloabium ATCC 31962 Provides Indications for Its Taxonomic Reclassification.

Authors:  Henrike Miess; Patricia Arlt; Alexander Kristian Apel; Tilmann Weber; Kay Nieselt; Friederike Hanssen; Stefan Czemmel; Sven Nahnsen; Harald Gross
Journal:  Microbiol Resour Announc       Date:  2019-11-07

6.  Integrated Omics Strategy Reveals Cyclic Lipopeptides Empedopeptins from Massilia sp. YMA4 and Their Biosynthetic Pathway.

Authors:  Shang-Tse Ho; Ying-Ning Ho; Chih Lin; Wei-Chen Hsu; Han-Jung Lee; Chia-Chi Peng; Han-Tan Cheng; Yu-Liang Yang
Journal:  Mar Drugs       Date:  2021-04-09       Impact factor: 5.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.